Carlos Iribarren to Hypersensitivity
This is a "connection" page, showing publications Carlos Iribarren has written about Hypersensitivity.
Connection Strength
0.925
-
Cardiovascular and cerebrovascular events among patients receiving omalizumab: Pooled analysis of patient-level data from 25 randomized, double-blind, placebo-controlled clinical trials. J Allergy Clin Immunol. 2017 05; 139(5):1678-1680.
Score: 0.568
-
Asthma and the prospective risk of anaphylactic shock and other allergy diagnoses in a large integrated health care delivery system. Ann Allergy Asthma Immunol. 2010 May; 104(5):371-7.
Score: 0.357